|
| Lysosomotropic Agent | | Model | Effective doses | Reference |
|
| Siramesine | In vitro | Breast cancer lines: Mcf-7, Mcf-10A, and MDA-MB-468 | 1–10 μM | [18, 19, 30] |
| Cervix carcinoma cell lines: HeLa and ME-180 | 1–10 μM |
| Colorectal cancer cell lines: Hkh2 and HCT116 | 8 μM |
| Fibroblast cell line: NIH3&3-SrcY527F | 4–10 μM |
| Fibrosarcoma cell lines: WEHI-S and R4 | 5 μM |
| Mast cells (primary) | 2–20 μM |
| Osteosarcoma cell line: U2OS | 1–10 μM |
| Ovarian carcinoma cell line: SKOV3 | 8–10 μM |
| Prostate cancer cell lines: PC3 and Du145-P | 5–10 μM |
| In vivo | WEHI-R4 in BALB-c mice | 25–100 mg/kg/d |
| Mcf-7 in SCID mice | 30–100 mg/kg/d |
| PC3-MDR in SCID mice | 30 mg/kg |
|
| Desipramine | In vitro | Breast cancer lines: Mcf-7 and Mcf-10A | 25 μM | [19] |
| Cervix carcinoma cell line: HeLa | 25–50 μM |
| Colorectal cancer cell lines: Hkh2 and HCT116 | 8 μM |
| Fibroblast cell line: NIH3&3-SrcY527F | 8–25 μM |
| Osteosarcoma cell line: U2OS | 25–50 μM |
| Ovarian carcinoma cell line: SKOV3 | 75–100 μM |
| Prostate cancer cell lines: PC3 and Du145-P | 5–10 μM |
| In vivo | Mcf-7 in SCID mice | 30 mg/kg, 2×/wk |
|
| Nortriptyline | In vitro | Breast cancer line: Mcf-7 | 25–50 μM | [19] |
| Cervix carcinoma cell line: HeLa | 25–50 μM |
| Colorectal cancer cell lines: Hkh2 and HCT116 | 8 μM |
| Fibroblast cell line: NIH3&3-SrcY527F | 10–25 μM |
| Osteosarcoma cell line: U2OS | 25–50 μM |
| Ovarian carcinoma cell line: SKOV3 | 40–60 μM |
| Prostate cancer cell lines: PC3 and Du145-P | 40–80 μM |
|
| Amlodipine | In vitro | Breast cancer line: Mcf-7 | 25–50 μM | [19] |
| Fibroblast cell line: NIH3&3-SrcY527F | 10–30 μM |
| Ovarian carcinoma cell line: SKOV3 | 37.5–50 μM |
| Prostate cancer cell lines: PC3 and Du145-P | 40–50 μM |
|
| Terfenadine | In vitro | Breast cancer line: Mcf-7 | 25–50 μM | [19] |
| Colorectal cancer cell lines: Hkh2 and HCT116 | 8 μM |
| Fibroblast cell line: NIH3&3-SrcY527F | 2.5–5 μM |
| Ovarian carcinoma cell line: SKOV3 | 6–8 μM |
| Prostate cancer cell lines: PC3 and Du145-P | 1–10 μM |
| In vivo | Mcf-7 in SCID mice | 10 mg/kg, 2×/wk |
|
| Mefloquine | In vitro | AML cells (primary) | 5–15 μM | [14] |
| AML cell lines: HL60, KG1A OCI-AML2, and TEX | 1–10 μM |
| APL cell line: NB4 | 5–7 μM |
| CML cell line: K562 | 6–10 μM |
| Dendritic cells (primary) | 25–50 μM |
| Erythroleukemic cell line: OCI-M2 | 7–9 μM |
Gastric cancer cell lines: AGS, Hs746T, MKN45, MKN74,
NCI-N87, SNU1, SNU16, TCC1, YCC10, and YCC11 | 0.5–5 μM |
| Lymphosarcoma cell line: MDAY-D2 | 3–5 μM |
| Macrophage/monocyte cell lines: THP-1 and U937 | 5–18 μM |
| Oral cancer cell line: KVP20C | 5 μM |
| Prostate cancer cell line: PC3 | 5–40 μM |
| In vivo | K562, MDAY-D2, and OCI-AML2 in NOD-SCID mice | 50 mg/kg |
| Primary AML cells in NOD-SCID mice | 100 mg/kg/d |
| YCC or SNU1 in SCID mice | Unknown |
| PC3 in C57B1/6J mice | 200 μg/25 mg |
|
| Primaquine | In vitro | Breast cancer cell line: Mcf-7 | 7 μM | [58] |
| Colon cancer cell lines: Caco-2 and HT-29 | 40–70 μM |
| Oral cancer cell line: KVB20C | 50–75 μM |
|
| Atovaquone | In vitro | Oral cancer cell line: KVB20C | 2–12.5 μM | [59] |
|
| Ciprofloxacin | In vitro | Cervix carcinoma cell line: HeLa | 10 μg/ml | [34] |
| Colorectal cancer cell line HCT116 | 1–5 μM |
|
| Pterostilbene | In vitro | AML cell lines: HL-60, MV4-11, and OCI-AML2 | 25–75 μM | [58] |
| Macrophage cell lines: THP-1 and U937 | 25–75 μM |
| Melanoma cell line: A375 | 10–50 μM |
|
